SLDB Share Price | Solid Biosciences, Inc. Stock Analysis & Recommendation

Q: How big is Solid Biosciences, Inc.?

Market Cap: As of Jun 18, Solid Biosciences, Inc. has a market capitalization of 357.35 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Solid Biosciences, Inc. reported net sales of 0.00 million and a net profit of -139.68 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 137.25 million and total assets of 188.66 million.

Q: What does Solid Biosciences, Inc. do?

Overview: Solid Biosciences, Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD) within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -39 Million (Quarterly Results - Mar 2025) Market cap: USD 357.35 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.03 Return on Equity: -45.26% Price to Book: 1.21Contact Details: Address: 141 Portland St Fl 5, CAMBRIDGE MA: 02139-1937 Tel: 1 617 3374680 Fax: 1 302 6555049 Website: https://www.solidbio.com/

Q: Is Solid Biosciences, Inc. overvalued or undervalued?

As of 14 August 2023, the valuation grade for Solid Biosciences, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued, given its negative financial metrics. The P/E ratio is not applicable due to the company being loss-making, while the Price to Book Value stands at 1.20. Notably, the ROE is a concerning -45.26%, reflecting substantial losses relative to equity.In comparison to its peers, Solid Biosciences, Inc. has a valuation of -2.6812, while Instil Bio, Inc. is at -3.7811 and Nkarta, Inc. is at -1.1544. These figures suggest that Solid Biosciences is underperforming relative to its industry counterparts. Additionally, the company's recent stock performance shows a 1-year return of -30.19%, contrasting sharply with the S&P 500's 10.26% return over the same period, further reinforcing the notion that it is overvalued in the current market environment.

Q: Is Solid Biosciences, Inc. technically bullish or bearish?

As of 4 August 2025, the technical trend for Solid Biosciences, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while weekly MACD and Dow Theory show mildly bearish signals. The Bollinger Bands are bullish on the weekly timeframe but bearish on the monthly. The stock has performed well in the short term with a 1-week return of 2.45% compared to the S&P 500's 1.05%, but it has underperformed over longer periods, with a 1-year return of -23.81% versus the S&P 500's 17.14%.

Results Declared: Solid Biosciences, Inc. has declared results on 19 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

941.08 k

Shareholding (Dec 2025)

FII

8.59%

Held by 50 FIIs

DII

44.16%

Held by 26 DIIs

Promoter

31.29%

How big is Solid Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Solid Biosciences, Inc. has a market capitalization of 357.35 million, with net sales of 0.00 million and a net profit of -139.68 million over the latest four quarters. The company reported shareholder's funds of 137.25 million and total assets of 188.66 million as of Dec 24.

View full answer

What does Solid Biosciences, Inc. do?

22-Jun-2025

Solid Biosciences, Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD). It has a market cap of $357.35 million and reported a net profit loss of $39 million as of March 2025.

View full answer

Who are in the management team of Solid Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Solid Biosciences, Inc. includes Ian Smith (Chairman), Ilan Ganot (CEO), and several independent directors: Matthew Arnold, Martin Freed, Robert Huffines, Adam Koppel, and Sukumar Nagendran.

View full answer

Is Solid Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of August 14, 2023, Solid Biosciences, Inc. is considered overvalued with a valuation grade of "does not qualify," a Price to Book Value of 1.20, a troubling ROE of -45.26%, and a 1-year stock return of -30.19%, significantly underperforming compared to its peers and the S&P 500.

View full answer

Is Solid Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 4, 2025, Solid Biosciences, Inc. shows a mildly bullish trend, supported by daily moving averages, despite mixed signals from weekly MACD and Dow Theory, with a short-term return of 2.45% compared to the S&P 500's 1.05%, but a long-term underperformance of -23.81% versus the S&P 500's 17.14%.

View full answer

Compare Solid Biosciences, Inc. with Similar Stocks

OKYO Pharma Ltd.Instil Bio, Inc.Rani Therapeutics Holdings, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 583 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.07

Return on Equity

-72.95%

Price to Book

2.67

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-50 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

21.02%

6 Months

33.96%

1 Year

55.22%

2 Years

-48.07%

3 Years

89.39%

4 Years

-62.22%

5 Years

-91.36%

Solid Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-23.70%

EBIT to Interest (avg)

-106.52

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.03

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.67

EV to EBIT

-2.06

EV to EBITDA

-2.08

EV to Capital Employed

-21.97

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-72.95%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 25 Schemes (15.96%)

Foreign Institutions

Held by 50 Foreign Institutions (8.59%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -8.73% vs -15.95% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-48.90",
          "val2": "-47.70",
          "chgp": "-2.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.70",
          "val2": "-0.80",
          "chgp": "-237.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-49.80",
          "val2": "-45.80",
          "chgp": "-8.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -39.78% vs -29.90% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-177.60",
          "val2": "-127.30",
          "chgp": "-39.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.00",
          "val2": "-4.70",
          "chgp": "-27.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-174.30",
          "val2": "-124.70",
          "chgp": "-39.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-48.90

-47.70

-2.52%

Interest

0.00

Exceptional Items

-2.70

-0.80

-237.50%

Consolidate Net Profit

-49.80

-45.80

-8.73%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -8.73% vs -15.95% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-177.60

-127.30

-39.51%

Interest

0.00

0.30

-100.00%

Exceptional Items

-6.00

-4.70

-27.66%

Consolidate Net Profit

-174.30

-124.70

-39.78%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -39.78% vs -29.90% in Dec 2024

All Annual Results

Company CV

About Solid Biosciences, Inc.

Solid Biosciences, Inc.

Pharmaceuticals & Biotechnology

Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.

Company Coordinates

Company Details

141 Portland St Fl 5 , CAMBRIDGE MA : 02139-1937

Tel: 1 617 33746801 617 3374680

https://www.solidbio.com/

Registrar Details